Entremed (ENMD)

[Dr Jerry]

it not only activates native p53 gene but it has some ability to inactivate mutant p53 during cell cycle regeneration.
It basically has the ability to ameliorate mutant p53 and the phase 1 trial is actively ongoing at Dana Farber and they are probably onto the 5th cohort and have not reached MTD nor has there been any severe adverse reactions.
How about using both Kevetrin and ENMD 2076 in triple negative breast cancer that shows over expression of mutant p53??
Dont want to jump ahead too far,stay tuned.